HDAC family: What are the cancer relevant targets?

The Consensus Coding Sequences of Human Breast and Colorectal Cancers

Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161 · see citing works

Histone deacetylases (HDACs): characterization of the classical HDAC family

RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114 · see citing works

Anticancer activities of histone deacetylase inhibitors

Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919 · see citing works

Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain

Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559 · see citing works

HDAC6 is a microtubule-associated deacetylase

Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X.-F., & Yao, T.-P. (2002) · Nature · doi:10.1038/417455a · Cited by 2,403 · see citing works

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

Minucci, S., & Pelicci, P. G. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1779 · Cited by 2,211 · see citing works

A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p

Taunton, J., Hassig, C. A., & Schreiber, S. L. (1996) · Science · doi:10.1126/science.272.5260.408 · Cited by 1,829 · see citing works

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714 · see citing works

The Deacetylase HDAC6 Regulates Aggresome Formation and Cell Viability in Response to Misfolded Protein Stress

Kawaguchi, Y., Kovacs, J. J., McLaurin, A. C., Vance, J. M., Ito, A., & Yao, T. (2003) · Cell · doi:10.1016/s0092-8674(03)00939-5 · Cited by 1,529 · see citing works

Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis

Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456 · see citing works

The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men

Yang, X., & Seto, E. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2346 · Cited by 1,239 · see citing works

HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS.

Pandey, U. B., Nie, Z., Batlevi, Y., McCray, B. A., Ritson, G. P., Nedelsky, N. B., Schwartz, S. L., DiProspero, N. A., Knight, M. A., Schuldiner, O., et al. (2007) · Nature · doi:10.1038/nature05853 · Cited by 1,234 · see citing works

Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug

Marks, P. A., & Breslow, R. (2007) · Nature Biotechnology · doi:10.1038/nbt1272 · Cited by 1,198 · see citing works

Histone Deacetylase Inhibitors: Overview and Perspectives

Dokmanovic, M., Clarke, C., & Marks, P. A. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0324 · Cited by 1,173 · see citing works

HDAC6 Regulates Hsp90 Acetylation and Chaperone-Dependent Activation of Glucocorticoid Receptor

Kovacs, J. J., Murphy, P. J. M., Gaillard, S., Zhao, X., Wu, J.-T., Nicchitta, C. V., Yoshida, M., Toft, D. O., Pratt, W. B., & Yao, T.-P. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.021 · Cited by 1,153 · see citing works

Histone deacetylase inhibitor selectively induces p21 ^WAF1 expression and gene-associated histone acetylation

Richon, V. M., Sandhoff, T. W., Rifkind, R. A., & Marks, P. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180316197 · Cited by 1,090 · see citing works

Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation

Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0430973100 · Cited by 1,066 · see citing works

Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation

McKinsey, T. A., Zhang, C., Lu, J., & Olson, E. N. (2000) · Nature · doi:10.1038/35040593 · Cited by 1,051 · see citing works

Class II Histone Deacetylases Act as Signal-Responsive Repressors of Cardiac Hypertrophy

Zhang, C. L., McKinsey, T. A., Chang, S., Antos, C. L., Hill, J. A., & Olson, E. N. (2002) · Cell · doi:10.1016/s0092-8674(02)00861-9 · Cited by 973 · see citing works

Deacetylation of p53 modulates its effect on cell growth and apoptosis

Luo, J., Su, F., Chen, D., Shiloh, A., & Gu, W. J. (2000) · Nature · doi:10.1038/35042612 · Cited by 818 · see citing works

Histone Deacetylase 4 Controls Chondrocyte Hypertrophy during Skeletogenesis

Vega, R. B., Matsuda, K., Oh, J., Barbosa, A. C. C., Yang, X., Meadows, E., McAnally, J., Pomajzl, C., Shelton, J. M., Richardson, J. A., et al. (2004) · Cell · doi:10.1016/j.cell.2004.10.024 · Cited by 805 · see citing works

Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression

Lagger, G., O'Carroll, D., Rembold, M., Khier, H., Tischler, J., Weitzer, G., Schuettengruber, B., Hauser, C., Brunmeir, R., Jenuwein, T., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/21.11.2672 · Cited by 760 · see citing works

Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90

Bali, P., Pranpat, M., Bradner, J., Balasis, M., Fiskus, W., Guo, F., Rocha, K., Kumaraswamy, S., Boyapalle, S., Atadja, P., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500186200 · Cited by 755 · see citing works

Untitled work

(2002) · PubMed · Cited by 732 · see citing works

Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractilityPreprint

Montgomery, R. L., Davis, C. A., Potthoff, M. J., Haberland, M., Fielitz, J., Qi, X., Hill, J. A., Richardson, J. A., & Olson, E. N. (2007) · Genes & Development · doi:10.1101/gad.1563807 · Cited by 716 · see citing works

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

Khan, N., Jeffers, M., Kumar, S., Hackett, C., Boldog, F., Khramtsov, N., Qian, X., Mills, E., Berghs, S. C., Carey, N., et al. (2008) · Biochemical Journal · doi:10.1042/bj20070779 · Cited by 713 · see citing works

A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors

Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., & Nakanishi, O. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4592 · Cited by 696 · see citing works

Class II histone deacetylases: versatile regulators

Verdin, E., Dequiedt, F., & Kasler, H. G. (2003) · Trends in Genetics · doi:10.1016/s0168-9525(03)00073-8 · Cited by 664 · see citing works

Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor

Vannini, A., Volpari, C., Filocamo, G., Casavola, E. C., Brunetti, M., Renzoni, D., Chakravarty, P., Paolini, C., De Francesco, R., Gallinari, P., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404603101 · Cited by 638 · see citing works

HDA1 and RPD3 are members of distinct yeast histone deacetylase complexes that regulate silencing and transcription

Rundlett, S. E., Carmen, A. A., Kobayashi, R., Bavykin, S. G., Turner, B. M., & Grunstein, M. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14503 · Cited by 618 · see citing works

Histone Deacetylases 5 and 9 Govern Responsiveness of the Heart to a Subset of Stress Signals and Play Redundant Roles in Heart Development

Chang, S., McKinsey, T. A., Zhang, C. L., Richardson, J. A., Hill, J. A., & Olson, E. N. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8467-8476.2004 · Cited by 612 · see citing works

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

Hideshima, T., Bradner, J. E., Wong, J. Y. Y., Chauhan, D., Richardson, P. G. G., Schreiber, S. L., & Anderson, K. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503221102 · Cited by 598 · see citing works

Mice Lacking Histone Deacetylase 6 Have Hyperacetylated Tubulin but Are Viable and Develop Normally

Zhang, Y., Kwon, S., Yamaguchi, T., Cubizolles, F., Rousseaux, S., Kneissel, M., Cao, C., Li, N., Cheng, H.-L., Chua, K., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01154-06 · Cited by 559 · see citing works

Histone deacetylase (HDAC) inhibitor activation of p21 WAF1 involves changes in promoter-associated proteins, including HDAC1

Gui, C., Ngo, L., Xu, W., Richon, V. M., & Marks, P. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307708100 · Cited by 550 · see citing works

p21 WAF1 is required for butyrate-mediated growth inhibition of human colon cancer cells

Archer, S. Y., Meng, S., Shei, A., & Hodin, R. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.12.6791 · Cited by 534 · see citing works

Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase.

Kijima, M., Yoshida, M., Sugita, K., Horinouchi, S., & Beppu, T. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41547-5 · Cited by 516 · see citing works

Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer

Halkidou, K., Gaughan, L., Cook, S., Leung, H. Y., Neal, D. E., & Robson, C. N. (2004) · The Prostate · doi:10.1002/pros.20022 · Cited by 515 · see citing works

Protein Kinases C and D Mediate Agonist-Dependent Cardiac Hypertrophy through Nuclear Export of Histone Deacetylase 5

Vega, R. B., Harrison, B. C., Meadows, E., Roberts, C. R., Papst, P. J., Olson, E. N., & McKinsey, T. A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8374-8385.2004 · Cited by 512 · see citing works

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

Sandor, V. A., Bakke, S., Robey, R. W., Kang, M. H., Blagosklonny, M. V., Bender, J., Brooks, R. A., Piekarz, R., Tucker, E. E., Figg, W. D., et al. (2002) · PubMed · Cited by 504 · see citing works

Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy

Weichert, W., Roske, A.-E., Gekeler, V., Beckers, T. L., Stephan, C., Jung, K., Fritzsche, F., Niesporek, S., Denkert, C., Dietel, M., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604199 · Cited by 478 · see citing works

Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3β activity

Trivedi, C. M., Luo, Y., Yin, Z., Zhang, M., Zhu, W., Wang, T., Floß, T., Göttlicher, M., Ruíz, P., Wurst, W., et al. (2007) · Nature Medicine · doi:10.1038/nm1552 · Cited by 469 · see citing works

Untitled work

(2003) · PubMed · Cited by 465 · see citing works

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

Garcia‐Manero, G., Yang, H., Bueso-Ramos, C., Ferrajoli, A., Cortes, J. E., Wierda, W. G., Faderl, S. H., Koller, C. A., Morris, G., Rosner, G. L., et al. (2007) · Blood · doi:10.1182/blood-2007-06-098061 · Cited by 460 · see citing works

A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas

Balasubramanian, S., Ramos, J., Luo, W., Sirisawad, M., Verner, E., & Buggy, J. J. (2008) · Leukemia · doi:10.1038/leu.2008.9 · Cited by 458 · see citing works

MEF2C Transcription Factor Controls Chondrocyte Hypertrophy and Bone Development

Arnold, M., Kim, Y., Czubryt, M. P., Phan, D., McAnally, J., Qi, X., Shelton, J. M., Richardson, J. A., Bassel‐Duby, R., & Olson, E. N. (2007) · Developmental Cell · doi:10.1016/j.devcel.2007.02.004 · Cited by 456 · see citing works

Histone Deacetylase 7 Maintains Vascular Integrity by Repressing Matrix Metalloproteinase 10

Chang, S., Young, B. D., Li, S., Qi, X., Richardson, J. A., & Olson, E. N. (2006) · Cell · doi:10.1016/j.cell.2006.05.040 · Cited by 454 · see citing works

Vorinostat

Grant, S., Easley, C., & Kirkpatrick, P. J. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2227 · Cited by 417 · see citing works

Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma

Ryan, Q. C., Headlee, D. J., Acharya, M. R., Sparreboom, A., Trepel, J. B., Ye, Z., Figg, W. D., Hwang, K., Chung, E. J., Murgo, A. J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.188 · Cited by 412 · see citing works

The deacetylase HDAC6 is a novel critical component of stress granules involved in the stress responsePreprint

Kwon, S., Zhang, Y., & Matthias, P. (2007) · Genes & Development · doi:10.1101/gad.461107 · Cited by 402 · see citing works

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia

Byrd, J. C. (2004) · Blood · doi:10.1182/blood-2004-05-1693 · Cited by 400 · see citing works

Histone deacetylase 8 in neuroblastoma tumorigenesis

Oehme, I., Deubzer, H. E., Wegener, D., Pickert, D., Linke, J.-P., Hero, B., Kopp-Schneider, A., Westermann, F., Ulrich, S. M., von Deimling, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0684 · Cited by 398 · see citing works

Transcriptional repression by REST: recruitment of Sin3A and histone deacetylase to neuronal genes

Huang, Y., Myers, S. J., & Dingledine, R. J. (1999) · Nature Neuroscience · doi:10.1038/13165 · Cited by 397 · see citing works

NuRD and SIN3

Ahringer, J. (2000) · Trends in Genetics · doi:10.1016/s0168-9525(00)02066-7 · Cited by 388 · see citing works

The histone deacetylase-3 complex contains nuclear receptor corepressors

Wen, Y.-D., Perissi, V., Staszewski, L. M., Yang, W.-M., Krones, A., Glass, C. K., Rosenfeld, M. G., & Seto, E. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.13.7202 · Cited by 378 · see citing works

Deletion of Histone Deacetylase 3 Reveals Critical Roles in S Phase Progression and DNA Damage Control

Bhaskara, S., Chyla, B., Amann, J. M., Knutson, S. K., Cortez, D., Sun, Z., & Hiebert, S. W. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.02.030 · Cited by 369 · see citing works

Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo

Weichert, W., Roske, A.-E., Niesporek, S., Noske, A., Buckendahl, A., Dietel, M., Gekeler, V., Boehm, M., Beckers, T. L., & Denkert, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0990 · Cited by 362 · see citing works

Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis

Weichert, W., Roske, A.-E., Gekeler, V., Beckers, T. L., Ebert, M. P., Pross, M., Dietel, M., Denkert, C., & Röcken, C. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70004-4 · Cited by 361 · see citing works

Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases

Hu, E., Dul, E., Sung, C.-M., Chen, Z., Kirkpatrick, R. B., Zhang, G., Johanson, K., Liu, R., Lago, A. M., Hofmann, G. A., et al. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.055541 · Cited by 350 · see citing works

Expression Profile of Histone Deacetylase 1 in Gastric Cancer Tissues

Choi, J., Kwon, H. J., Yoon, B., Kim, J., Han, S., Joo, H. J., & Kim, D.-Y. (2001) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2001.tb02153.x · Cited by 349 · see citing works

Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1

Huang, B., Laban, M., Leung, C. H.-W., Lee, L., Lee, C. K., Salto‐Tellez, M., Raju, G. C., & Hooi, S. C. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401567 · Cited by 337 · see citing works

ETO, a Target of t(8;21) in Acute Leukemia, Makes Distinct Contacts with Multiple Histone Deacetylases and Binds mSin3A through Its Oligomerization Domain

Amann, J. M., Nip, J., Strom, D. K., Lutterbach, B. A., Harada, H., Lenny, N. T., Downing, J. R., Meyers, S., & Hiebert, S. W. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.19.6470-6483.2001 · Cited by 336 · see citing works

Quantitation of HDAC1 mRNA Expression in Invasive Carcinoma of the Breast*

Zhang, Z., Yamashita, H., Toyama, T., Sugiura, H., Ando, Y., Mita, K., Hamaguchi, M., Hara, Y., Kobayashi, S., & Iwase, H. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-6001-1 · Cited by 307 · see citing works

Class II Histone Deacetylases Are Associated with VHL-Independent Regulation of Hypoxia-Inducible Factor 1α

Qian, D. Z., Kachhap, S. K., Collis, S. J., Verheul, H. M. W., Carducci, M. A., Atadja, P. W., & Пили, Р. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4598 · Cited by 302 · see citing works

HDAC6 Expression Is Correlated with Better Survival in Breast Cancer

Zhang, Z., Yamashita, H., Toyama, T., Sugiura, H., Omoto, Y., Ando, Y., Mita, K., Hamaguchi, M., Hayashi, S., & Iwase, H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0455 · Cited by 295 · see citing works

A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition

Ropero, S., Fraga, M. F., Ballestar, E., Hamelin, R., Yamamoto, H., Boix-Chornet, M., Caballero, R., Alaminos, M., Setién, F., Paz, M. F., et al. (2006) · Nature Genetics · doi:10.1038/ng1773 · Cited by 290 · see citing works

Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias

Gojo, I., Jiemjit, A., Trepel, J. B., Sparreboom, A., Figg, W. D., Rollins, S., Tidwell, M. L., Greer, J. M., Chung, E. J., Lee, M.-J., et al. (2006) · Blood · doi:10.1182/blood-2006-05-021873 · Cited by 281 · see citing works

HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions

Tran, A. D.-A., Marmo, T. P., Salam, A. A., Che, S., Finkelstein, E., Kabarriti, R., Xenias, H. S., Mazitschek, R., Hubbert, C., Kawaguchi, Y., et al. (2007) · Journal of Cell Science · doi:10.1242/jcs.03431 · Cited by 281 · see citing works

Acetylation of p53 at Lysine 373/382 by the Histone Deacetylase Inhibitor Depsipeptide Induces Expression of p21Waf1/Cip1

Zhao, Y., Lu, S., Wu, L., Chai, G., Wang, H., Chen, Y., Sun, J. T., Yu, Y., Zhou, W., Zheng, Q., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.7.2782-2790.2006 · Cited by 277 · see citing works

Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin.

Han, J. W., Ahn, S. H., Park, S. H., Wang, S. Y., Bae, G., Seo, D. W., Kwon, H. K., Hong, S., Lee, H. Y., Lee, Y., et al. (2000) · PubMed · Cited by 273 · see citing works

Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks

Knutson, S. K., Chyla, B. J., Amann, J. M., Bhaskara, S., Huppert, S. S., & Hiebert, S. W. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.51 · Cited by 271 · see citing works

SIK1 is a class II HDAC kinase that promotes survival of skeletal myocytes

Berdeaux, R., Goebel, N., Banaszynski, L. A., Takemori, H., Wandless, T. J., Shelton, G. D., & Montminy, M. (2007) · Nature Medicine · doi:10.1038/nm1573 · Cited by 266 · see citing works

Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer

Saji, S., Kawakami, M., Hayashi, S., Yoshida, N., Hirose, M., Horiguchi, S.-I., Ito, A., Funata, N., Schreiber, S. L., Yoshida, M., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208646 · Cited by 259 · see citing works

Differential expression of selected histone modifier genes in human solid cancers

Özdağ, H., Teschendorff, A. E., Ahmed, A. A., Hyland, S. J., Blenkiron, C., Bobrow, L., Veerakumarasivam, A., Burtt, G. J., Subkhankulova, T., Arends, M. J., et al. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-90 · Cited by 258 · see citing works

Role for Histone Deacetylase 1 in Human Tumor Cell Proliferation

Senese, S., Zaragoza, K., Minardi, S. P., Muradore, I., Ronzoni, S., Passafaro, A., Bernard, L., Draetta, G. F., Alcalay, M., Seiser, C., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00494-07 · Cited by 253 · see citing works

Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell Lymphoma

Piekarz, R., Frye, A. R., Wright, J. J., Steinberg, S. M., Liewehr, D. J., Rosing, D. R., Sachdev, V., Fojo, T., & Bates, S. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2095 · Cited by 232 · see citing works

Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis

Krusche, C. A., W�lfing, P., Kersting, C., Vloet, A. J., B�cker, W., Kiesel, L., Beier, H. M., & Alfer, J. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-1668-2 · Cited by 230 · see citing works

MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors.

Jaboin, J. J., Wild, J., Hamidi, H., Khanna, C., Kim, C. J., Robey, R. W., Bates, S. E., & Thiele, C. J. (2002) · PubMed · Cited by 226 · see citing works

Role of Class I and Class II histone deacetylases in carcinoma cells using siRNA

Glaser, K. B., Li, J., Staver, M. J., Wei, R.-Q., Albert, D. H., & Davidsen, S. K. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.09.043 · Cited by 220 · see citing works

Design and evaluation of ‘Linkerless’ hydroxamic acids as selective HDAC8 inhibitors

KrennHrubec, K., Marshall, B. L., Hedglin, M., Verdin, E. M., & Ulrich, S. M. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.02.064 · Cited by 195 · see citing works

Histone Deacetylase 7 Silencing Alters Endothelial Cell Migration, a Key Step in Angiogenesis

Mottet, D., Bellahcène, A., Pirotte, S., Waltregny, D., Deroanne, C., Lamour, V., Lidereau, R., & Castronovo, V. (2007) · Circulation Research · doi:10.1161/circresaha.107.149377 · Cited by 192 · see citing works

Class II (IIa)-Selective Histone Deacetylase Inhibitors. 1. Synthesis and Biological Evaluation of Novel (Aryloxopropenyl)pyrrolyl Hydroxyamides

Mai, A., Massa, S., Pezzi, R., Simeoni, S., Rotili, D., Nebbioso, A., Scognamiglio, A., Altucci, L., Loidl, P., & Brosch, G. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049002a · Cited by 185 · see citing works

Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma

Sakuma, T., Uzawa, K., Onda, T., Shiiba, M., Yokoe, H., Shibahara, T., & Tanzawa, H. (2006) · International Journal of Oncology · doi:10.3892/ijo.29.1.117 · Cited by 185 · see citing works

Requirement of HDAC6 for Transforming Growth Factor-β1-induced Epithelial-Mesenchymal Transition

Shan, B., Yao, T., Nguyen, H. T., Zhuo, Y., Levy, D. R., Klingsberg, R. C., Tao, H., Palmer, M. L., Holder, K. N., & Lasky, J. A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802786200 · Cited by 176 · see citing works

HDAC6 Is Required for Epidermal Growth Factor-induced β-Catenin Nuclear Localization

Li, Y., Zhang, X., Polakiewicz, R. D., Yao, T., & Comb, M. J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.c700185200 · Cited by 174 · see citing works

Clinical Significance of Histone Deacetylase 1 Expression in Patients with Hepatocellular Carcinoma

Rikimaru, T., Taketomi, A., Yamashita, Y., Shirabe, K., Hamatsu, T., Shimada, M., & Maehara, Y. (2007) · Oncology · doi:10.1159/000111106 · Cited by 172 · see citing works

A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas

Gore, L., Rothenberg, M. L., O'Bryant, C. L., Schultz, M. K., Sandler, A. B., Coffin, D., McCoy, C., Schott, A., Scholz, C., & Eckhardt, S. G. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1461 · Cited by 171 · see citing works

Crystal Structure of a Bacterial Class 2 Histone Deacetylase Homologue

Nielsen, T. K., Hildmann, C., Dickmanns, A., Schwienhorst, A., & Ficner, R. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.09.065 · Cited by 157 · see citing works

Expression of Hypoxia-Inducible Factor-1α, Histone Deacetylase 1, and Metastasis-Associated Protein 1 in Pancreatic Carcinoma

Miyake, K., Yoshizumi, T., Imura, S., Sugimoto, K., Batmunkh, E., Kanemura, H., Morine, Y., & Shimada, M. (2008) · Pancreas · doi:10.1097/mpa.0b013e31815f2c2a · Cited by 155 · see citing works

Histone Deacetylase 2 Modulates p53 Transcriptional Activities through Regulation of p53-DNA Binding Activity

Harms, K. L., & Chen, X. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4397 · Cited by 152 · see citing works

Histone deacetylase 1 mRNA expression in lung cancer

Sasaki, H., Moriyama, S., Nakashima, Y., Kobayashi, Y., Kiriyama, M., Fukai, I., Yamakawa, Y., & Fujii, Y. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2004.03.021 · Cited by 143 · see citing works

Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells

Bruserud, Ø., Stapnes, C., Ersvær, E., Gjertsen, B. T., & Ryningen, A. (2007) · Current Pharmaceutical Biotechnology · doi:10.2174/138920107783018417 · Cited by 141 · see citing works

Synthesis of 7200 Small Molecules Based on a Substructural Analysis of the Histone Deacetylase Inhibitors Trichostatin and Trapoxin

Sternson, S. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. (2001) · Organic Letters · doi:10.1021/ol016915f · Cited by 139 · see citing works

Inhibition of Histone Deacetylase Class I but not Class II Is Critical for the Sensitization of Leukemic Cells to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis

Inoue, S., Mai, A., Dyer, M. J. S., & Cohen, G. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4563 · Cited by 131 · see citing works

Tolerability, Pharmacodynamics, and Pharmacokinetics Studies of Depsipeptide (Romidepsin) in Patients with Acute Myelogenous Leukemia or Advanced Myelodysplastic Syndromes

Klimek, V. M., Fircanis, S., Maslak, P. G., Guernah, I., Baum, M., Wu, N. F., Panageas, K. S., Wright, J. J., Pandolfi, P. P., & Nimer, S. D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0318 · Cited by 130 · see citing works

Reduced Body Size and Decreased Intestinal Tumor Rates in HDAC2-Mutant Mice

Zimmermann, S., Kiefer, F., Prudenziati, M., Spiller, C., Hansen, J., Floß, T., Wurst, W., Minucci, S., & Göttlicher, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0312 · Cited by 129 · see citing works

Histone Deacetylase Inhibitor Depsipeptide Activates Silenced Genes through Decreasing both CpG and H3K9 Methylation on the Promoter

Wu, L., Wang, X., Li, L., Zhao, Y., Lu, S., Yu, Y., Zhou, W., Liu, X., Yang, J., Zheng, Z., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01516-07 · Cited by 123 · see citing works

Functional Differences in Epigenetic ModulatorsSuperiority of Mercaptoacetamide-Based Histone Deacetylase Inhibitors Relative to Hydroxamates in Cortical Neuron Neuroprotection Studies

Kozikowski, A. P., Chen, Y., Gaysin, A. M., Chen, B., D’Annibale, M. A., Suto, C. M., & Langley, B. C. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070178x · Cited by 122 · see citing works

Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors

Siu, L. L., Пили, Р., Durán, I., Messersmith, W. A., Chen, E. X., Sullivan, R., MacLean, M., King, S., Brown, S., Reid, G. K., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5730 · Cited by 117 · see citing works

Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin

Schrump, D. S., Fischette, M. R., Nguyen, D. M., Zhao, M., Li, X., Kunst, T. F., Hancox, A., Hong, J. A., Chen, G. A., Kruchin, E., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0135 · Cited by 117 · see citing works

An expression screen reveals modulators of class II histone deacetylase phosphorylation

Chang, S., Bezprozvannaya, S., Li, S., & Olson, E. N. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503275102 · Cited by 108 · see citing works

Design, Synthesis, Structure−Selectivity Relationship, and Effect on Human Cancer Cells of a Novel Series of Histone Deacetylase 6-Selective Inhibitors

Itoh, Y., Suzuki, T., Kouketsu, A., Suzuki, N., Maeda, S., Yoshida, M., Nakagawa, H., & Miyata, N. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm7009217 · Cited by 106 · see citing works

Highly Potent and Selective Histone Deacetylase 6 Inhibitors Designed Based on a Small-Molecular Substrate

Suzuki, T., Kouketsu, A., Itoh, Y., Hisakawa, S., Maeda, S., Yoshida, M., Nakagawa, H., & Miyata, N. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060554y · Cited by 105 · see citing works

Histone Deacetylase 1 Gene Expression and Sensitization of Multidrug-Resistant Neuroblastoma Cell Lines to Cytotoxic Agents by Depsipeptide

Keshelava, N., Davicioni, E., Wan, Z., Ji, L., Sposto, R., Triche, T. J., & Reynolds, C. P. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm044 · Cited by 102 · see citing works

Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors

Park, J., Kim, S.-H., Choi, M.-C., Lee, J., Oh, D., Im, S., Bang, Y., & Kim, T.-Y. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.01.056 · Cited by 98 · see citing works

Inhibition of histone deacetylase1 induces autophagy

Oh, M., Choi, I.-K., & Kwon, H. J. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.03.019 · Cited by 97 · see citing works

Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin

Schrump, D. S., Fischette, M. R., Nguyen, D. M., Zhao, M., Li, X., Kunst, T. F., Hancox, A., Hong, J. A., Chen, G. A., Kruchin, E., et al. (2007) · Clinical Lung Cancer · doi:10.1016/s1525-7304(11)70818-x · Cited by 97 · see citing works

Genetic variants in epigenetic genes and breast cancer risk

Cebrián, A., Pharoah, P. D. P., Ahmed, S., Ropero, S., Fraga, M. F., Smith, P. L., Conroy, D. M., Luben, R., Perkins, B., Easton, D. F., et al. (2006) · Carcinogenesis · doi:10.1093/carcin/bgi375 · Cited by 96 · see citing works

Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation

Watamoto, K., Towatari, M., Ozawa, Y., Miyata, Y., Okamoto, M., Abe, A., Naoe, T., & Saito, H. (2003) · Oncogene · doi:10.1038/sj.onc.1206902 · Cited by 95 · see citing works

Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2)

Witter, D. J., Harrington, P., Wilson, K. J., Chenard, M., Fleming, J. C., Haines, B., Kral, A. M., Secrist, J. P., & Miller, T. A. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.11.047 · Cited by 93 · cited 1× · see citing works

R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies

Arts, J., Angibaud, P. R., Mariën, A., Floren, W., Janssens, B., King, P., Dun, J. V., Janssen, L., Geerts, T., Tuman, R. W., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604025 · Cited by 89 · see citing works

Selective Inhibition of Histone Deacetylase 2 Silences Progesterone Receptor–Mediated Signaling

Biçaku, E., Marchion, D. C., Schmitt, M. L., & Münster, P. N. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2822 · Cited by 88 · see citing works

Histone Deacetylase 8 Safeguards the Human Ever-Shorter Telomeres 1B (hEST1B) Protein from Ubiquitin-Mediated Degradation

Lee, H., Sengupta, N., Villagra, A., Rezai‐Zadeh, N., & Seto, E. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01971-05 · Cited by 86 · see citing works

Phase I Study of Depsipeptide in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Report

Fouladi, M., Furman, W. L., Chin, T. K., Freeman, B. B., Dudkin, L., Stewart, C. F., Krailo, M., Speights, R., Ingle, A. M., Houghton, P. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4964 · Cited by 82 · see citing works

HDAC4 mediates transcriptional repression by the acute promyelocytic leukaemia-associated protein PLZF

Chauchereau, A., Mathieu, M., de Saintignon, J., Ferreira, R., Pritchard, L. L., Mishal, Z., Dejean, A., & Harel‐Bellan, A. (2004) · Oncogene · doi:10.1038/sj.onc.1208128 · Cited by 78 · see citing works

2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors

JONES, P. G., Bottomley, M. J., Carfı́, A., Cecchetti, O., Ferrigno, F., Surdo, P. L., Ontoria, J. M., Rowley, M., Scarpelli, R., Schultz‐Fademrecht, C., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.02.026 · Cited by 64 · see citing works

Identification of novel substrates for human checkpoint kinase Chk1 and Chk2 through genome-wide screening using a consensus Chk phosphorylation motif

Kim, M.-A., Kim, H., Brown, A. L., Lee, M.-Y., Bae, Y., Park, J., Kwak, J.-Y., Chung, J. H., & Yun, J. (2007) · Experimental & Molecular Medicine · doi:10.1038/emm.2007.23 · Cited by 61 · see citing works

Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARα as a component of the N-CoR co-repressor complex to repress transcription in vivo

Atsumi, A., Tomita, A., Kiyoi, H., & Naoe, T. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.05.047 · Cited by 51 · see citing works

Bispyridinium Dienes: Histone Deacetylase Inhibitors with Selective Activities

Pérez‐Balado, C., Nebbioso, A., Rodríguez‐Graña, P., Minichiello, A., Miceli, M., Altucci, L., & de Lera, Á. R. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070028m · Cited by 49 · see citing works

Histone deacetylase inhibitor Helminthosporium carbonum (HC)‐toxin suppresses the malignant phenotype of neuroblastoma cells

Deubzer, H. E., Ehemann, V., Westermann, F., Heinrich, R., Mechtersheimer, G., Kulozik, A. E., Schwab, M., & Witt, O. (2007) · International Journal of Cancer · doi:10.1002/ijc.23295 · Cited by 40 · see citing works

HDAC10 promoter polymorphism associated with development of HCC among chronic HBV patients

Park, B. L., Kim, Y. J., Cheong, H. S., Lee, S. O., Han, C. S., Yoon, J., Park, J. H., Chang, H. S., Park, C., Lee, H.-S., et al. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.09.026 · Cited by 37 · see citing works

Anti-neuroblastoma activity of Helminthosporium carbonum (HC)-toxin is superior to that of other differentiating compounds in vitro

Deubzer, H. E., Ehemann, V., Kulozik, A. E., Westermann, F., Savelyeva, L., Kopp‐Schneider, A., Riester, D., Schwab, M., & Witt, O. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.01.002 · Cited by 30 · see citing works

No Association between Polymorphisms in theHistone DeacetylaseGenes and the Risk of Lung Cancer

Park, J. M., Lee, G. Y., Choi, J. E., Kang, H. G., Jang, J. S., Ick, S., Lee, E. B., Kim, S. G., Kim, C. H., Lee, W. K., et al. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0200 · Cited by 12 · see citing works

Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME

Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280 · see citing works

Oral squamous cell carcinomas: state of the field and emerging directions

Tan, Y., Wang, Z., Xu, M., Li, B., Huang, Z., Qin, S., Nice, E. C., Tang, J., & Huang, C. (2023) · International Journal of Oral Science · doi:10.1038/s41368-023-00249-w · Cited by 924 · see citing works

Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A

Butler, K. V., Kalin, J., Brochier, C., Vistoli, G., Langley, B., & Kozikowski, A. P. (2010) · Journal of the American Chemical Society · doi:10.1021/ja102758v · Cited by 801 · see citing works

The world of protein acetylation

Drazic, A., Myklebust, L. M., Ree, R., & Arnesen, T. (2016) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2016.06.007 · Cited by 799 · see citing works

New Perspectives on How to Discover Drugs from Herbal Medicines: CAM's Outstanding Contribution to Modern Therapeutics

Pan, S.-Y., Zhou, S.-F., Gao, S.-H., Yu, Z., Zhang, S.-F., Tang, M.-K., Sun, J.-N., Ma, D., Han, Y., Fong, W. F., et al. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/627375 · Cited by 723 · see citing works

MicroRNAs and epigenetics

Sato, F., Tsuchiya, S., Meltzer, S. J., & Shimizu, K. (2011) · FEBS Journal · doi:10.1111/j.1742-4658.2011.08089.x · Cited by 586 · see citing works

Class IIa Histone Deacetylases Are Hormone-Activated Regulators of FOXO and Mammalian Glucose Homeostasis

Mihaylova, M. M., Vasquez, D. S., Ravnskjær, K., Denechaud, P., Yu, R. T., Alvarez, J. G. A., Downes, M., Evans, R. M., Montminy, M., & Shaw, R. J. (2011) · Cell · doi:10.1016/j.cell.2011.03.043 · Cited by 554 · see citing works

Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors

Delcuve, G. P., Khan, D. H., & Davie, J. R. (2012) · Clinical Epigenetics · doi:10.1186/1868-7083-4-5 · Cited by 505 · see citing works

Epigenetics in cancer: Targeting chromatin modifications

Ellis, L., Atadja, P. W., & Johnstone, R. W. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0860 · Cited by 483 · see citing works

HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications

Khan, O., & La Thangue, N. B. (2012) · Immunology & Cell Biology · doi:10.1038/icb.2011.100 · Cited by 450 · see citing works

Rational approaches, design strategies, structure activity relationship and mechanistic insights for anticancer hybrids

Nepali, K., Sharma, S., Sharma, M., Bedi, P. M. S., & Dhar, K. L. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.03.018 · Cited by 445 · see citing works

Role of Zinc in Immune System and Anti-Cancer Defense Mechanisms

Skrajnowska, D., & Bobrowska‐Korczak, B. (2019) · Nutrients · doi:10.3390/nu11102273 · Cited by 426 · see citing works

Targeted Cancer Therapy: Giving Histone Deacetylase Inhibitors All They Need To Succeed

Gryder, B. E., Sodji, Q. H., & Oyelere, A. K. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.3 · Cited by 404 · see citing works

Selective in vivo metabolic cell-labeling-mediated cancer targeting

Wang, H., Wang, R., Cai, K., He, H., Liu, Y., Yen, J. S., Wang, Z., Xu, M., Sun, Y., Zhou, X., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2297 · Cited by 387 · see citing works

Post-translational modifications of tubulin: pathways to functional diversity of microtubules

Song, Y., & Brady, S. T. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.10.004 · Cited by 377 · see citing works

Indole in the target-based design of anticancer agents: A versatile scaffold with diverse mechanisms.

Dadashpour, S., & Emami, S. (2018) · European journal of medicinal chemistry · doi:10.1016/j.ejmech.2018.02.065 · Cited by 280 · see citing works

Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes

Li, Y., Shin, D., & Kwon, S. H. (2012) · FEBS Journal · doi:10.1111/febs.12079 · Cited by 346 · see citing works

HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?

Simões-Pires, C., Zwick, V., Nurisso, A., Schenker, E., Carrupt, P.-A., & Cuendet, M. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-7 · Cited by 341 · see citing works

Histone deacetylase 6 in cancer

Li, T., Zhang, C., Hassan, S., Liu, X., Song, F., Chen, K., Zhang, W., & Yang, J. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0654-9 · Cited by 330 · see citing works

Inside HDACs with more selective HDAC inhibitors

Roche, J., & Bertrand, P. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.05.047 · Cited by 323 · see citing works

HDAC inhibitor‐based therapies: Can we interpret the code?

New, M. I., Olzscha, H., & Thangue, N. B. L. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.003 · Cited by 310 · see citing works

MicroRNA epigenetic signatures in human disease

Piletič, K., & Kunej, T. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1815-7 · Cited by 302 · see citing works

The Redox Basis of Epigenetic Modifications: From Mechanisms to Functional Consequences

Cyr, A. R., & Domann, F. E. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3492 · Cited by 294 · see citing works

HDAC8: a multifaceted target for therapeutic interventions

Chakrabarti, A., Oehme, I., Witt, O., Oliveira, G., Sippl, W., Romier, C., Pierce, R. J., & Jung, M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.013 · Cited by 284 · see citing works

Target engagement and drug residence time can be observed in living cells with BRET

Robers, M. B., Dart, M. L., Woodroofe, C. C., Zimprich, C., Kirkland, T. A., Machleidt, T., Kupcho, K. R., Levin, S., Hartnett, J. R., Zimmerman, K., et al. (2015) · Nature Communications · doi:10.1038/ncomms10091 · Cited by 275 · see citing works

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

Ocio, E. M., Richardson, P. G. G., Rajkumar, S. V., Palumbo, A. P., Mateos, M., Orlowski, R. Z., Kumar, S. K., Usmani, S. Z., Roodman, D., Niesvizky, R., et al. (2013) · Leukemia · doi:10.1038/leu.2013.350 · Cited by 232 · see citing works

Glioblastoma stem cells (GSCs) epigenetic plasticity and interconversion between differentiated non-GSCs and GSCs

Safa, A. R., Saadatzadeh, M. R., Cohen‐Gadol, A., Pollok, K. E., & Bijangi‐Vishehsaraei, K. (2015) · Genes & Diseases · doi:10.1016/j.gendis.2015.02.001 · Cited by 230 · see citing works

Inhibitors of histone deacetylase as antitumor agents: A critical review

Mohammed, M., Chandrasekar, M., Jeyapal, G. P., & Nanjan, M. J. (2016) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2016.05.005 · Cited by 227 · see citing works

Isoform-specific histone deacetylase inhibitors: The next step?

Balasubramanian, S., Verner, E. J., & Buggy, J. J. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.013 · Cited by 224 · see citing works

Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy

Singh, A. K., Bishayee, A., & Pandey, A. K. (2018) · Nutrients · doi:10.3390/nu10060731 · Cited by 224 · see citing works

Molecular hybridization: a powerful tool for multitarget drug discovery

Pinheiro, P. D. S. M., Franco, L. S., Montagnoli, T. L., & Fraga, C. A. M. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2322990 · Cited by 224 · see citing works

Histone deacetylase 10 promotes autophagy-mediated cell survival

Oehme, I., Linke, J.-P., Böck, B. C., Milde, T., Lodrini, M., Hartenstein, B., Wiegand, I., Eckert, C., Roth, W., Kool, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300113110 · Cited by 221 · see citing works

Histone Deacetylase 6 in Health and Disease

Seidel, C., Schnekenburger, M., Dicato, M. A., & Diederich, M. F. (2015) · Epigenomics · doi:10.2217/epi.14.69 · Cited by 216 · see citing works

Histone Deacetylases Activate Hepatocyte Growth Factor Signaling by Repressing MicroRNA-449 in Hepatocellular Carcinoma Cells

Buurman, R., Gürlevik, E., Schäffer, V., Eilers, M., Sandbothe, M., Kreipe, H. H., Wilkens, L., Schlegelberger, B., Kühnel, F., & Skawran, B. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.033 · Cited by 211 · see citing works

research paper: Differential expression of <i>HDAC3, HDAC7</i> and <i>HDAC9</i> is associated with prognosis and survival in childhood acute lymphoblastic leukaemia

Moreno, D. A., Scrideli, C. A., Cortez, M. A. A., De Paula Queiroz, R., Valera, E. T., Da Silva Silveira, V., Yunes, J. A., Brandalise, S. R., & Tone, L. G. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08301.x · Cited by 208 · see citing works

HDAC5 and HDAC9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth

Milde, T., Oehme, I., Korshunov, A., Kopp‐Schneider, A., Remke, M., Northcott, P. A., Deubzer, H. E., Lodrini, M., Taylor, M. D., von Deimling, A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0395 · Cited by 192 · see citing works

Three-Dimensional Cell Growth Confers Radioresistance by Chromatin Density Modification

Storch, K., Eke, I., Borgmann, K., Krause, M., Richter, C., Becker, K., Schröck, E., & Cordes, N. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3848 · Cited by 191 · see citing works

Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts

Pipalia, N. H., Cosner, C. C., Huang, A. Y., Chatterjee, A., Bourbon, P., Farley, N., Helquist, P. M., Wiest, O., & Maxfield, F. R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014890108 · Cited by 186 · see citing works

Histone Deacetylase (HDAC) Inhibitors with a Novel Connecting Unit Linker Region Reveal a Selectivity Profile for HDAC4 and HDAC5 with Improved Activity against Chemoresistant Cancer Cells

Marek, L., Hamacher, A., Hansen, F. K., Kuna, K., Gohlke, H., Kassack, M. U., & Kurz, T. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301254q · Cited by 185 · see citing works

Epigenetic Modifications and Head and Neck Cancer: Implications for Tumor Progression and Resistance to Therapy

CASTILHO, R. M., SQUARIZE, C. H., & Almeida, L. O. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071506 · Cited by 185 · see citing works

Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation

Rettig, I., Koeneke, E., Trippel, F., Mueller, W. C., Burhenne, J., Kopp‐Schneider, A., Fabian, J., Schober, A., Fernekorn, U., von Deimling, A., et al. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.24 · Cited by 184 · see citing works

Driver mutations of cancer epigenomes

Roy, D. M., Walsh, L. A., & Chan, T. A.-T. (2014) · Protein & Cell · doi:10.1007/s13238-014-0031-6 · Cited by 183 · see citing works

The histone deacetylase 4/SP1/microrna-200a regulatory network contributes to aberrant histone acetylation in hepatocellular carcinoma

Yuan, J., Yang, F., Chen, B.-F., Lu, Z. J., Huo, X., Zhou, W., Wang, F., & Sun, S. (2010) · Hepatology · doi:10.1002/hep.24606 · Cited by 180 · see citing works

Histone Deacetylase Inhibitors In The Treatment Of Cancer: Overview And Perspectives

Giannini, G., Cabri, W., Fattorusso, C., & Rodriquez, M. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.80 · Cited by 178 · see citing works

Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma

Mithraprabhu, S., Kalff, A., Chow, A. L., Khong, T. T., & Spencer, A. G. (2014) · Epigenetics · doi:10.4161/15592294.2014.983367 · Cited by 176 · see citing works

Histone deacetylase inhibitors facilitate partner preference formation in female prairie voles

Wang, H., Duclot, F., Liu, Y., Wang, Z., & Kabbaj, M. (2013) · Nature Neuroscience · doi:10.1038/nn.3420 · Cited by 173 · see citing works

Histone Deacetylases

Parbin, S., Kar, S., Shilpi, A., Sengupta, D., Deb, M., Rath, S. K., & Patra, S. K. (2013) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155413506582 · Cited by 172 · see citing works

Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China

Lu, X., Ning, Z., Li, Z., Cao, H., & Wang, X. (2016) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2016.01024 · Cited by 172 · see citing works

Activation of Histone Deacetylase-6 Induces Contractile Dysfunction Through Derailment of α-Tubulin Proteostasis in Experimental and Human Atrial Fibrillation

Zhang, D., Wu, C.-T., Qi, X., Meijering, R. A. M., Hoogstra‐Berends, F., Tadevosyan, A., Deniz, G. Ç., Durdu, S., Akar, A. R., Sibon, O. C. M., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.005300 · Cited by 171 · see citing works

HDAC inhibitors and immunotherapy; a double edged sword?

Kroesen, M., Gielen, P. R., Brok, I. C., Armandari, I., Hoogerbrugge, P. M., & Adema, G. J. (2014) · Oncotarget · doi:10.18632/oncotarget.2289 · Cited by 167 · see citing works

Epigenetic regulation in mammalian preimplantation embryo development

Shi, L., & Wu, J. (2009) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-7-59 · Cited by 163 · see citing works

Regulating the Regulators: The Post‐Translational Code of Class I HDAC1 and HDAC2

Segré, C. V., & Chiocca, S. (2010) · BioMed Research International · doi:10.1155/2011/690848 · Cited by 154 · see citing works

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8

Yan, W., Liu, S., Xu, E., Zhang, J., Zhang, Y., Chen, X., & Chen, X. (2013) · Oncogene · doi:10.1038/onc.2012.81 · Cited by 153 · see citing works

Cytotoxicity Mediated by Histone Deacetylase Inhibitors in Cancer Cells: Mechanisms and Potential Clinical Implications

Schrump, D. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2787 · Cited by 152 · see citing works

Hdac7 promotes lung tumorigenesis by inhibiting Stat3 activation

Lei, Y., Liu, L., Zhang, S., Guo, S., Li, X., Wang, J., Su, B., Fang, Y., Chen, X., Ke, H., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0736-2 · Cited by 152 · see citing works

Epigenetics and MicroRNAs in Cancer

Ramassone, A., Pagotto, S., Veronese, A., & Visone, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020459 · Cited by 149 · see citing works

Histone Deacetylase Inhibition with Valproic Acid Downregulates Osteocalcin Gene Expression in Human Dental Pulp Stem Cells and Osteoblasts: Evidence for HDAC2 Involvement

Paino, F., Noce, M. L., Tirino, V., Naddeo, P., Desiderio, V., Pirozzi, G., ROSA, A. D., Laino, L., Altucci, L., & Papaccio, G. (2013) · Stem Cells · doi:10.1002/stem.1544 · Cited by 148 · see citing works

Reactive Oxygen Species-generating Mitochondrial DNA Mutation Up-regulates Hypoxia-inducible Factor-1α Gene Transcription via Phosphatidylinositol 3-Kinase-Akt/Protein Kinase C/Histone Deacetylase Pathway

Koshikawa, N., Hayashi, J.-I., Nakagawara, A., & Takenaga, K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.054221 · Cited by 147 · see citing works

Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy

Verza, F. A., Das, U., Fachin, A. L., Dimmock, J. R., & Marins, M. (2020) · Cancers · doi:10.3390/cancers12061664 · Cited by 147 · see citing works

Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis

Korfei, M., Skwarna, S., Henneke, I., MacKenzie, B., Klymenko, O., Saito, S., Ruppert, C., von der Beck, D., Mahavadi, P., Klepetko, W., et al. (2015) · Thorax · doi:10.1136/thoraxjnl-2014-206411 · Cited by 143 · see citing works

Histone Modifications in Senescence-Associated Resistance to Apoptosis by Oxidative Stress

Sanders, Y. Y., Liu, H., Zhang, X., Hecker, L., Bernard, K., Desai, L., Liu, G., & Thannickal, V. J. (2013) · Redox Biology · doi:10.1016/j.redox.2012.11.004 · Cited by 138 · see citing works

Histone Deacetylase Inhibition and Dietary Short-Chain Fatty Acids

Licciardi, P. V., Ververis, K., & Karagiannis, T. C. (2011) · ISRN Allergy · doi:10.5402/2011/869647 · Cited by 138 · see citing works

Histone deacetylase (HDAC) inhibitors reduce the glial inflammatory response in vitro and in vivo

Faraco, G., Pittelli, M. G., Cavone, L., Fossati, S., Porcu, M., Mascagni, P., Fossati, G., Moroni, F., & Chiarugi, A. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.019 · Cited by 138 · see citing works

SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer

Novotny‐Diermayr, V., Sangthongpitag, K., Hu, C. Y., Wu, X., Sausgruber, N., Yeo, P., Greicius, G., Pettersson, S., Liang, A. L., Loh, Y. K., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0689 · Cited by 138 · see citing works

Development and therapeutic impact of HDAC6-selective inhibitors

Dallavalle, S., Pisano, C., & Zunino, F. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.06.014 · Cited by 137 · see citing works

Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells

Fiegler, N., Textor, S., Arnold, A., Rölle, A., Oehme, I., Breuhahn, K., Moldenhauer, G., Witzens‐Harig, M., & Cerwenka, A. (2013) · Blood · doi:10.1182/blood-2013-02-482513 · Cited by 135 · see citing works

Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein

Venkataramani, V., Rossner, C., Iffland, L., Schweyer, S., Tamboli, I. Y., Walter, J., Wirths, O., & Bayer, T. A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.057836 · Cited by 133 · see citing works

Histone Deacetylase (HDAC) 10 Suppresses Cervical Cancer Metastasis through Inhibition of Matrix Metalloproteinase (MMP) 2 and 9 Expression

Song, C., Zhu, S., Wu, C., & Kang, J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.498758 · Cited by 133 · see citing works

HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment

Milde, T., Lodrini, M., Savelyeva, L., Korshunov, A., Kool, M., Brueckner, L. M., Antunes, A. S. L. M., Oehme, I., Pekrun, A., Pfister, S. M., et al. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0978-1 · Cited by 131 · see citing works

HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins

Jung, K. H., Noh, J. H., Kim, J. K., Eun, J. W., Bae, H. J., Xie, H. J., Chang, Y. G., Kim, M., Park, H., Lee, J. Y., et al. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24090 · Cited by 130 · see citing works

Development and Therapeutic Implications of Selective Histone Deacetylase 6 Inhibitors

Kalin, J. H., & Bergman, J. A. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4001659 · Cited by 129 · see citing works

Targeting Histone Deacetylases in Diseases: Where Are We?

Benedetti, R., Conte, M., & Altucci, L. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5776 · Cited by 127 · see citing works

Revisit dietary fiber on colorectal cancer: butyrate and its role on prevention and treatment

Encarnação, J. C., Abrantes, A. M., Pires, A. S., & Botelho, M. F. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9578-9 · Cited by 126 · see citing works

Regulation of microRNAs by epigenetics and their interplay involved in cancer

Liu, X., Chen, X., Yu, X., Tao, Y., Bode, A. M., Dong, Z., & Cao, Y. (2013) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-32-96 · Cited by 125 · see citing works

Potent and Selective Inhibition of Histone Deacetylase 6 (HDAC6) Does Not Require a Surface-Binding Motif

Wagner, F. F., Olson, D. E., Gale, J. P., Kaya, T., Weïwer, M., Aidoud, N., Thomas, M., Davoine, E. L., Lemercier, B. C., Zhang, Y., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301355j · Cited by 121 · see citing works

Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases

Felice, C., Lewis, A., Armuzzi, A., Lindsay, J., & Silver, A. R. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13008 · Cited by 120 · see citing works

Invasive Cell Fate Requires G1 Cell-Cycle Arrest and Histone Deacetylase-Mediated Changes in Gene Expression

Matus, D. Q., Lohmer, L. L., Kelley, L. C., Schindler, A. J., Kohrman, A. Q., Barkoulas, M., Zhang, W., Chi, Q., & Sherwood, D. R. (2015) · Developmental Cell · doi:10.1016/j.devcel.2015.10.002 · Cited by 119 · see citing works

Patchouli alcohol, an essential oil of Pogostemon cablin, exhibits anti-tumorigenic activity in human colorectal cancer cells

Jeong, J. B., Choi, J., Lou, Z., Jiang, X., & Lee, S. (2013) · International Immunopharmacology · doi:10.1016/j.intimp.2013.04.006 · Cited by 119 · see citing works

Strategies To Design Selective Histone Deacetylase Inhibitors

Melesina, J., Simoben, C. V., Praetorius, L., Bülbül, E. F., Robaa, D., & Sippl, W. (2021) · ChemMedChem · doi:10.1002/cmdc.202000934 · Cited by 118 · see citing works

MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer

Noh, J. H., Chang, Y. G., Kim, M. G., Jung, K. H., Kim, J. K., Bae, H. J., Eun, J. W., Shen, Q., Kim, S.-J., Kwon, S. H., et al. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.03.003 · Cited by 118 · see citing works

Cancer metabolism: New insights into classic characteristics

Kato, Y., Maeda, T., Suzuki, A., & Baba, Y. (2017) · Japanese Dental Science Review · doi:10.1016/j.jdsr.2017.08.003 · Cited by 117 · see citing works

Histone Acetylation Modifiers in the Pathogenesis of Alzheimer’s Disease

Lu, X., Wang, L., Yu, C., Yu, D., & Yu, G. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00226 · Cited by 116 · see citing works

Targeting histone acetylation in pulmonary hypertension and right ventricular hypertrophy

Chelladurai, P., Boucherat, O., Stenmark, K. R., Kracht, M., Seeger, W., Bauer, U., Bonnet, S., & Pullamsetti, S. S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14932 · Cited by 116 · see citing works

Commensal microbiota regulates T cell fate decision in the gut

Furusawa, Y., Obata, Y., & Hase, K. (2014) · Seminars in Immunopathology · doi:10.1007/s00281-014-0455-3 · Cited by 114 · see citing works

HDAC1 Inactivation Induces Mitotic Defect and Caspase-Independent Autophagic Cell Death in Liver Cancer

Xie, H. J., Noh, J. H., Kim, J. K., Jung, K. H., Eun, J. W., Bae, H. J., Kim, M., Chang, Y. G., Lee, J. Y., Park, H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034265 · Cited by 114 · see citing works

Design, Synthesis, and Pharmacological Evaluation of Novel N -Acylhydrazone Derivatives as Potent Histone Deacetylase 6/8 Dual Inhibitors

Rodrigues, D. A., Ferreira‐Silva, G. Á., Ferreira, A. C. S., Fernandes, R. A., Kwee, J. K., Sant’Anna, C. M. R., Ionta, M., & Fraga, C. A. M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01525 · Cited by 113 · see citing works

Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview

Banerjee, S., Adhikari, N., Amin, S. A., & Jha, T. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.039 · Cited by 113 · see citing works

HDAC11 is a novel drug target in carcinomas

Deubzer, H. E., Schier, M. C., Oehme, I., Lodrini, M., Haendler, B., Sommer, A., & Witt, O. (2013) · International Journal of Cancer · doi:10.1002/ijc.27876 · Cited by 112 · see citing works

Targeting Histone Deacetylase 8 as a Therapeutic Approach to Cancer and Neurodegenerative Diseases

Chakrabarti, A., Melesina, J., Kolbinger, F. R., Oehme, I., Senger, J., Witt, O., Sippl, W., & Jung, M. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0117 · Cited by 111 · see citing works

450K-array analysis of chronic lymphocytic leukemia cells reveals global DNA methylation to be relatively stable over time and similar in resting and proliferative compartments

Cahill, N., Bergh, A.-C., Kanduri, M., Göransson‐Kultima, H., Mansouri, L., Isaksson, A., Ryan, F., Smedby, K. E. E., Juliusson, G., Sundström, C., et al. (2012) · Leukemia · doi:10.1038/leu.2012.245 · Cited by 111 · see citing works

Inhibition of HDAC1 and DNMT1 Modulate RGS10 Expression and Decrease Ovarian Cancer Chemoresistance

Çaçan, E., Ali, M. W., Boyd, N., Hooks, S. B., & Greer, S. F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087455 · Cited by 110 · see citing works

Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe

Protomártir, M. C., Garcia-Alberich, C., Blasco-Angulo, N., Vall‐llaura, N., Nàger, M., Herreros, J., Comella, J. X., Sanchı́s, D., & Llovera, M. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.412 · Cited by 108 · see citing works

Inhibition of HDAC6 Activity Alleviates Myocardial Ischemia/Reperfusion Injury in Diabetic Rats: Potential Role of Peroxiredoxin 1 Acetylation and Redox Regulation

Leng, Y., Wu, Y., Lei, S., Zhou, B., Qiu, Z., Wang, K., & Xia, Z. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/9494052 · Cited by 108 · see citing works

Mechanisms of Resistance to Histone Deacetylase Inhibitors

Lee, J., Choy, M. L., & Marks, P. A. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-394387-3.00002-1 · Cited by 108 · see citing works

Histone deacetylase 6 functions as a tumor suppressor by activating c-Jun NH2-terminal kinase-mediated beclin 1-dependent autophagic cell death in liver cancer

Jung, K. H., Noh, J. H., Kim, J. K., Eun, J. W., Bae, H. J., Chang, Y. G., Kim, M., Park, W. S., Lee, J. Y., Lee, S.-Y., et al. (2012) · Hepatology · doi:10.1002/hep.25699 · Cited by 108 · see citing works

Second-Generation Histone Deacetylase 6 Inhibitors Enhance the Immunosuppressive Effects of Foxp3+ T-Regulatory Cells

Kalin, J. H., Butler, K. V., Akimova, T., Hancock, W. W., & Kozikowski, A. P. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200773h · Cited by 105 · see citing works

A Nuclear‐Targeted AIE Photosensitizer for Enzyme Inhibition and Photosensitization in Cancer Cell Ablation

Wang, K., Liu, L., Mao, D., Hou, M., Tan, C., Mao, Z., & Liu, B. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202114600 · Cited by 105 · see citing works

Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer

Botrugno, O. A., Santoro, F., & Minucci, S. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.027 · Cited by 104 · see citing works

Targeting histone deacetylases in T-cell lymphoma

Moskowitz, A. J., & Horwitz, S. M. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1247956 · Cited by 103 · see citing works

Progress in the Research of Selective Histone Deacetylase Inhibitors

Lü, S. (2010) · The Chinese Journal of Modern Applied Pharmacy

In Silico Approaches Towards Safe Targeting of Class I Histone Deacetylases

Ganai, S. A. (2015) · Springer eBooks · doi:10.1007/978-1-4614-6436-5_459-1 · Cited by 11 · see citing works

5 Histone Deacetylase Inhibitors: A Novel Class of Anti-Cancer Agents on its Way to the Market

Körner, M., & Tibes, U. (2008) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(07)00005-7 · Cited by 13 · see citing works

Protected from the inside: Endogenous histone deacetylase inhibitors and the road to cancer

Marcotullio, L. D., Canettieri, G., Infante, P., Greco, A., & Gulino, A. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.01.002 · Cited by 51 · see citing works

Targeting class I histone deacetylases in cancer therapy

Delcuve, G. P., Khan, D. H., & Davie, J. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.729042 · Cited by 65 · see citing works